CTSO - シトソ―ベンツ （Cytosorbents Corporation）CTSOのニュース
Cytosorbents Corporation (CTSO) Q1 2023 Earnings Call Transcript 2023/05/03 02:11:03 Seeking Alpha
Cytosorbents Corporation (NASDAQ:NASDAQ:CTSO) Q1 2023 Results Earnings Conference Call May 2, 2023 4:30 AM ETCompany ParticipantsTaylor Devlin - Revenue AccountantPhillip Chan - Chief…
Cytosorbents GAAP EPS of -$0.17 misses by $0.02, revenue of $9.44M beats by $0.71M 2023/05/02 20:21:07 Seeking Alpha
Cytosorbents press release (NASDAQ:CTSO): Q1 GAAP EPS of -$0.17 misses by $0.02.Revenue of $9.44M (+8.6% Y/Y) beats by $0.71M.
A Preview Of CytoSorbents''s Earnings 2023/05/01 17:02:19 Benzinga
CytoSorbents (NASDAQ: CTSO ) is set to give its latest quarterly earnings report on Tuesday, 2023-05-02. Here''s what investors need to know before the announcement. Analysts estimate that CytoSorbents will report an earnings per share (EPS) of $-0.13. CytoSorbents bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com
CytoSorbents to Report First Quarter 2023 Operating and Financial Results 2023/04/26 11:00:00 GlobeNewswire
MONMOUTH JUNCTION, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2023 operating and financial results after the market close on Tuesday, May 2, 2023. CytoSorbents’ management will host a live presentation webcast and a question and answer session at 4:30PM EDT the same day.
Cytosorbents Pivotal STAR-T Trial Reaches Second Key Milestone 2023/04/20 11:05:02 Investing.com
https://www.investing.com/news/assorted/cytosorbents-pivotal-start-trial-reaches-second-key-milestone-432SI-3060389
CytoSorbents Earnings Preview 2023/03/08 14:01:51 Benzinga
CytoSorbents (NASDAQ: CTSO ) is set to give its latest quarterly earnings report on Thursday, 2023-03-09. Here''s what investors need to know before the announcement. Analysts estimate that CytoSorbents will report an earnings per share (EPS) of $-0.17. CytoSorbents bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com
CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference 2023/02/27 12:00:00 PR Newswire
PRINCETON, N.J., Feb. 27, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present…
CytoSorbents to Report Fiscal 2022 Operating and Financial Results 2023/02/24 12:00:00 PR Newswire
MONMOUTH JUNCTION, N.J., Feb. 24, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2022 financial results on Thursday, March 9,…
Cytosorbents Corporation (CTSO) will benefit from these strategies 2023/02/07 13:48:00 US Post News
The share price of Cytosorbents Corporation (NASDAQ:CTSO) rose to $4.17 per share on Monday from $3.56. While Cytosorbents Corporation has overperformed by 17.13%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CTSO rose by 12.70%, with highs and lows ranging from $4.15 to $1.03, whereas the […]
CytoSorbents guides Q4 revenue above estimates 2023/01/31 13:03:30 Seeking Alpha
Medical device company CytoSorbents (CTSO) reported on Tuesday its preliminary results, expecting total revenue of ~$34.7M (consensus: $33.57M) for 2022.The company generated $43.2M in…
CytoSorbents CFO to retire 2022/10/07 11:24:00 Seeking Alpha
CytoSorbents (CTSO) CFO Kathleen Bloch plans to retire on Mar. 31, 2023.
CytoSorbents secures $4.3M contract by U.S. Department of Defense 2022/10/06 11:27:04 Seeking Alpha
CytoSorbents (CTSO) notifies that the U.S. Army Medical Research Acquisition Activity has awarded the company a three-year Phase III contract valued at $4,292,641 to enable…
CytoSorbents Awarded an Approximately $4.3M Contract by the U.S. Department of Defense to Develop HemoDefend-BGA™ for Freeze-Dried Universal Plasma 2022/10/06 11:00:00 Benzinga
PRINCETON, N.J. , Oct. 6, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO ), a critical care immunotherapy leader specializing in blood purification, announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded the Company a three-year Phase III contract valued at $4,292,641 to customize the design of the HemoDefend-BGA™ filter for sterile integration into collections systems for freeze-dried plasma processing to generate freeze-dried universal plasma. Without the need for blood typing, widespread availability of universal plasma could help save lives via faster emergency treatment in both civilian and military settings. CTSO ) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents'' flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval of DrugSorb™-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto/CytoSorbents Corporation)" alt="CytoSorbents Corporation (NASDAQ: CTSO ) is a leader in the treatment of life-threatening conditions using blood purification.
CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey 2022/09/27 12:21:00 PR Newswire
CytoSorb®, DrugSorb®-ATR, and ECOS-300CY® now cleared for manufacturing from this site PRINCETON, N.J., Sept. 27, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using…